Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

thingsthatmakeyougohmmmmm 8 posts  |  Last Activity: May 23, 2016 8:29 PM Member since: Apr 19, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    AA Approval Coming...

    by bionerd51 May 22, 2016 8:36 AM
    thingsthatmakeyougohmmmmm thingsthatmakeyougohmmmmm May 23, 2016 8:29 PM Flag

    Interesting FDA approved Zohydro even after an 11-2 vote against approval. After watching the entire eteplirsen adcom meeting online, I have to believe FDA will utlimately grant conditional approval for eteplirsen. It is just the right thing to do.

    As Janet Woodcock stated at the adcom, "Finally, I would note that much of the effort in evaluating a drug development program goes into avoiding a specific mistake. That is, erroneously approving a drug that is not effective. There is often little consideration of another error, which is failing to approve a drug that actually works. In devastating diseases the consequences of this mistake can be extreme, but most of these consequences are borne by patients who traditionally have little say in how the standards are implemented."

    httpsCOLON//wwwDOTyoutubeDOTcom/watch?v=OsPoPq65ZCQ&feature=youtu.be&t=24m55s

  • thingsthatmakeyougohmmmmm thingsthatmakeyougohmmmmm Apr 25, 2016 11:57 PM Flag

    Go to the link to see the entire article. Here's the main takeaway:

    They learned that elevated T cell levels in the glioblastoma tumor predicted a longer survival time and that significant overlap in sequence between T cell receptors in the tumor and in the peripheral blood was correlated with extended survival.

    Prins told Clinical Informatics News that identifying matching T cell receptor sequences in the tumor and in the peripheral blood gives the researchers important new information, “You can see whether an immune response has been mounted after vaccination.”

    The results suggest that patients who have higher levels of TIL and have matching T cell receptors sequences in the tumor and peripheral blood already have some level of immune response that can be boosted with dendritic cell therapy. Patients that don't have any T cells inside their tumors, have little response. “Their immune systems were ignorant or ‘tolerized’ to the tumor; they didn't seem to respond as well,” said Prins.

  • thingsthatmakeyougohmmmmm by thingsthatmakeyougohmmmmm Apr 25, 2016 11:44 PM Flag

    httpCOLON//wwwDOTclinicalinformaticsnewsDOTcom/2016/4/25/sequencing-predicts-cancer-vaccine-outcome.aspx

    By Catherine Shaffer

    April 25, 2016 | A new study by UCLA researchers demonstrates the use of next generation sequencing to predict survival of brain cancer patients treated with a cancer vaccine. The vaccine, an autologous dendritic cell therapy called DCVax-L, is under development by Northwest Biotherapeutics Inc., of Bethesda, Md., for glioblastoma multiforme (GBM). It is designed to activate the adaptive immune system, including T lymphocytes (T cells).

    The study was published last month in Cancer Immunology Research (doi: 10.1158/2326-6066).

    In a Phase I/II clinical trial of DCVax-L in 39 patients with glioblastoma, median survival was three years, or around 2.5 times the usual duration of survival for patients receiving standard of care treatment only. However, there was a large difference between subgroups of patients who showed significant benefit from the therapy and subgroups who appeared to receive no benefit at all.

    The clinical trial lead investigator, Linda Liau, and her collaborator Robert Prins at the University of California, Los Angeles, teamed up with Seattle, Wash.-based Adaptive Biotechnologies Corp. to revisit the clinical trial data for deep sequencing of the T cell receptors inside the tumors and in peripheral blood. The technology allowed the team to quantitatively measure tumor-infiltrating lymphocytes (TILs) and compare specific T cell receptor sequences between tumor and peripheral blood.

    They learned that elevated T cell levels in the glioblastoma tumor predicted a longer survival time and that significant overlap in sequence between T cell receptors in the tumor and in the peripheral blood was correlated with extended survival.

    Prins told Clinical Informatics Ne

  • thingsthatmakeyougohmmmmm thingsthatmakeyougohmmmmm Apr 15, 2016 3:34 PM Flag

    I should also add:

    Sean Parker and StandUp2Cancer.

    "One of Parker's best friends, prominent Hollywood producer Laura Ziskin, founded Stand up to Cancer, and she was instrumental in shaping Parker's thinking about the disease. She died of complications from breast cancer in 2011."
    http://tinyurlDOTcom/h6yvhd8

    And of course, Allan Butler, one of the first patients in the phase 1 DCVax-Direct trial was featured on StandUp2Cancer in 2014:
    http://tinyurlDOTcom/z57cn9j

    Looks like he's alive, well, living life, and working today:
    http://tinyurlDOTcom/jrye85j

  • thingsthatmakeyougohmmmmm thingsthatmakeyougohmmmmm Apr 15, 2016 3:05 PM Flag

    I read this to mean when good news comes, NWBO will see HUGE buying pressure. I also believe Woodford is not going to wait for said news, he is going to start buying again before there is a run up. He is also likely paying close attention to Sean Parker's Institute for Cancer Immunotherapy. I'm sure he has people that can garner information on that $250 million kick-start fund. Adam Feuerstein is spouting expletives on twitter over that fund. It likely put a wrench in his short friends' attempts to kill disruptive therapies like DCVax-L and DCVax-Direct.

    So, are you a friend of AF?

  • thingsthatmakeyougohmmmmm thingsthatmakeyougohmmmmm Apr 15, 2016 2:16 PM Flag

    BTW, this update was delivered and dated today, April 15, 2016. It is new information, not from last month.

  • thingsthatmakeyougohmmmmm by thingsthatmakeyougohmmmmm Apr 15, 2016 1:17 PM Flag

    He continues to hold NWBO, and in fact sold off some other holdings "to provide capital to take advantage of the profound and unjustified share price weakness in several earlier-stage opportunities". He is practically disclosing he is planning for new buys in NWBO among other "earlier-stage opportunities" in the near future.

    http://tinyurlDOTcom/jhbruqr

    "US biotech business Prothena also rallied strongly following extreme and unjustified weakness earlier in the year. Elsewhere among our US biotech holdings, we also saw a modestly positive contribution from Theravance Biopharma and Alkermes but Northwest Biotherapeutics continued to decline as sentiment towards the company remained weak in the absence of any news.

    In terms of disposals, we sold the positions in AstraZeneca, Legal & General and Provident Financial. Redde, meanwhile, was significantly reduced. In each instance, we remain attracted to the long-term investment case but the positions were sold to provide capital to take advantage of the profound and unjustified share price weakness in several earlier-stage opportunities and to finance the new unquoted additions which look similarly attractive in valuation terms."

  • thingsthatmakeyougohmmmmm thingsthatmakeyougohmmmmm Apr 14, 2016 11:46 AM Flag

    from iHub #58959:

    Sean Parker and StandUp2Cancer.

    "One of Parker's best friends, prominent Hollywood producer Laura Ziskin, founded Stand up to Cancer, and she was instrumental in shaping Parker's thinking about the disease. She died of complications from breast cancer in 2011."
    http://wwwDOTcnnDOTcom/2016/04/13/health/cancer-immunotherapy-sean-parker/indexDOThtml?eref=rss_latest

    And of course, Allan Butler, one of the first patients in the phase 1 DCVax-Direct trial was featured on StandUp2Cancer in 2014:
    https://wwwDOTfacebookDOTcom/natgeotvUS/videos/10100434831905439/

    Looks like he's alive, well, living life, and working today:
    https://wwwDOTlinkedinDOTcom/in/allan-butler-a647b716

NBS
2.250.00(0.00%)Jun 5 3:59 PMEDT